Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fisch

Showing results (191-200 of 193) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 193 results.
European Journal of Cardiology|September 1, 1978
Definition of terms related to cardiac rhythm. WHO/ISFC Task ForceE O Robles de Medina, R Bernard, P Coumel, et al.
Virology|November 28, 2006
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120Simon Beddows, Michael Franti, Antu K Dey, et al.
Leukemia Research|June 23, 2022
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer centerTamer Othman, Benjamin N Moskoff, Gwendolyn Ho, et al.
Pageof 20

Showing results (191-200 of 193) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 193 results.
European Journal of Cardiology|September 1, 1978
Definition of terms related to cardiac rhythm. WHO/ISFC Task ForceE O Robles de Medina, R Bernard, P Coumel, et al.
Virology|November 28, 2006
A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120Simon Beddows, Michael Franti, Antu K Dey, et al.
Leukemia Research|June 23, 2022
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer centerTamer Othman, Benjamin N Moskoff, Gwendolyn Ho, et al.
Pageof 20